Fractyl Health, Inc. GUTS
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -96.38%
- 1 year
- -94.01%
5D +0.1650 (+20.61%)
- Market cap
- 12.67M
- Revenue (ttm)
- 97.00K
- EPS (ttm)
- -3.14
- Shares out
- 48.10M
- Forward P/E
- -0.77
- YTD return
- -96.38%
- 1-year return
- -94.01%
- Volume
- 223.26K
- Avg volume
- 501.11K
- Open
- 1.10
- Previous close
- 1.08
- Day's range
- 0.95 – 1.12
- 52-week range
- 0.80 – 29.34
- Price target
- 15.50 (+1522.5%)
Key statistics
- 50-day average
- 2.37
- 200-day average
- 4.29
- Enterprise value
- 64.36M
- Price / sales
- 942.14
- Price / book
- 1.82
- Revenue growth
- -61.10%
- Free cash flow
- -36.66M
- Total cash
- 84.66M
- Total debt
- 62.93M
- Return on equity
- -286.16%
- Short % of float
- 9.10%
Fundamental scorecard
2 of 25 checks passed on GUTS’s reported financials
2of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.50 | -0.48 | +0.02 | +4.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.46 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.46 | -0.36 | +0.10 | +21.74% |
| May 13, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.30 | -0.75 | -0.45 | -150.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 28, 2024 | Evercore ISI Group | init | — | Outperform |
| Feb 27, 2024 | Morgan Stanley | init | — | Overweight |
About Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fractyl.com
News
12 Health Care Stocks Moving In Monday's Intraday Session Canaccord Genuity Maintains Buy on Fractyl Health, Raises Price Target to $40
HC Wainwright & Co. Maintains Buy on Fractyl Health, Raises Price Target to $24
Fractyl Health, Inc. (GUTS) Q3 2026 Earnings Call Transcript Fractyl Health Q3 EPS $(1.07) Beats $(1.51) Estimate
Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates
12 Health Care Stocks Moving In Monday's After-Market Session Fractyl Health Expands Revita Patent Portfolio Ahead Of Planned FDA De Novo Submission
Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance
Canaccord Genuity Maintains Buy on Fractyl Health, Lowers Price Target to $39
Your note
Sign in to keep a note on GUTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMERICAN HOME ASSURANCE CO | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 5, 2024 | 283,878 |
| AMERICAN INTERNATIONAL GROUP, INC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 5, 2024 | 0 |
| CAPLAN JAY DAVID | President | Sale | Nov 10, 2024 | 631,160 |
| CVF LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 5, 2024 | 0 |
| ELIA MARC | Director | Purchase | Feb 5, 2024 | 0 |
| FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 5, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deer Management Co. LLC | 9.92% | 4,770,901 | 9.06M | Sep 29, 2024 |
| Hcc Manager LLC | 9.72% | 4,673,871 | 8.88M | Sep 29, 2024 |
| Maverick Capital Ltd. | 8.83% | 4,248,492 | 8.07M | Sep 29, 2024 |
| Blackrock Inc. | 4.64% | 2,232,516 | 4.24M | Sep 29, 2024 |
| M28 Capital Management LP | 3.86% | 1,856,117 | 3.53M | Sep 29, 2024 |
| Ensign Peak Advisors, Inc | 2.93% | 1,408,852 | 2.68M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.34% | 646,819 | 1.23M | Oct 30, 2024 |
| MFS New Discovery Fund | 1.33% | 639,147 | 1.21M | Aug 30, 2024 |
| MFS Variable Insurance Trust-MFS New Discovery Series | 0.41% | 195,104 | 370.70K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.40% | 194,797 | 370.11K | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.36% | 171,366 | 325.60K | Oct 30, 2024 |
| Pacific Select Fund-Small Cap Growth Portfolio | 0.30% | 143,198 | 272.08K | Sep 29, 2024 |
